BioRestorative Therapies (BRTX) Other Non-Current Liabilities (2013 - 2025)

BioRestorative Therapies (BRTX) has 13 years of Other Non-Current Liabilities data on file, last reported at $2.6 million in Q2 2025.

• Quarterly Other Non-Current Liabilities fell 42.56% year-over-year to $2.6 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $2.6 million (down 42.56% YoY) and the FY2024 annual result came in at $2.5 million, up 63.27% from the prior year.
• Other Non-Current Liabilities declined to $2.6 million in Q2 2025, from $3.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $10.8 million in Q4 2021 to a low of $1.5 million in Q4 2023.
• A 5-year average of $4.0 million and a median of $3.2 million in 2025 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2021 — Other Non-Current Liabilities surged 108042.06% — and 2023, when it plunged 72.14%.
• Tracing BRTX's Other Non-Current Liabilities over 5 years: stood at $10.8 million in 2021, then plunged by 48.76% to $5.5 million in 2022, then sank by 72.14% to $1.5 million in 2023, then surged by 63.27% to $2.5 million in 2024, then climbed by 2.36% to $2.6 million in 2025.
• The last three Other Non-Current Liabilities figures came in at $2.6 million (Q2 2025), $3.2 million (Q1 2025), and $2.5 million (Q4 2024), per Business Quant data.